<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515553</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1692</org_study_id>
    <secondary_id>2006-004283-31</secondary_id>
    <nct_id>NCT01515553</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 3a Formulation of Liraglutide (Formulation 4) and the Planned Phase 3b Formulation (Final Formulation 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of the
      phase 3a formulation of liraglutide (formulation 4) and the liraglutide formulation planned
      for phase 3b trials (final formulation 4).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (0-t)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, maximum concentration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (0-infinity)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative bioavailability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum (tmax)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half life (tÂ½)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Formulation 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Final formulation 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period</description>
    <arm_group_label>Formulation 4</arm_group_label>
    <arm_group_label>Final formulation 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general health as judged by the investigator, based on medical history, physical
             examination including 12-lead ECG (electrocardiogram), vital signs and blood and
             urinary laboratory assessments

          -  BMI (Body Mass Index) of 18.0-27.0 kg/m^2, both inclusive

        Exclusion Criteria:

          -  History of any clinically significant renal, hepatic, cardiovascular, pulmonary,
             gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric
             disease or other major disorders that may interfere with the objectives of the trial,
             as judged by the Investigator

          -  Impaired renal function

          -  Any clinically significant abnormal ECG, as judged by the Investigator

          -  Active hepatitis B and/or active hepatitis C

          -  Positive human immunodeficiency virus (HIV) antibodies

          -  Known or suspected allergy to trial product(s) or related products

          -  Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate
             contraceptive measures

          -  History of alcoholism or drug abuse, or positive results in alcohol or drug screens

          -  Smoking of more than 5 cigarettes per day, or the equivalent for other tobacco
             products

          -  Habitual excessive consumption of methylxanthine-containing (theophylline, caffeine or
             theobromine) beverages and foods (coffee, tea, soft drinks such as red bull, cola,
             chocolate) as judged by the Investigator

          -  Excessive consumption of a diet deviating from a normal diet as judged by the
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>January 12, 2015</last_update_submitted>
  <last_update_submitted_qc>January 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2015</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

